Table 1.
Group | n | Tension (mN) | pEC25 | pEC50 | R max (%)a |
---|---|---|---|---|---|
Control (0.01–0.03 μM U-46619 pre-constricted) | 21 | 10.0 ± 0.4 | 5.7 ± 0.1 | 5.0 ± 0.1 | 90 ± 7 |
–Endothelium | 7 | 13.7 ± 2.8 | – | – | 23 ± 11*** |
l-NAME (300) | 4 | 10.0 ± 1.1 | 4.2 ± 0.1*** | – | 36 ± 10*** |
Indomethacin (10) | 7 | 10.7 ± 1.8 | – | – | 28 ± 10*** |
l-NAME (300) + indomethacin (10) | 3 | 8.4 ± 0.8 | – | – | 11 ± 9*** |
RO1138452 (1) | 5 | 10.0 ± 2.0 | 4.5 ± 0.3** | – | 30 ± 5*** |
Iberiotoxin (0.1) | 5 | 8.7 ± 1.0 | 4.5 ± 0.1*** | – | 39 ± 8 |
URB597 (1) | 12 | 12.9 ± 1.5 | 5.1 ± 0.2* | 4.3 ± 0.1** | 65 ± 3** |
URB597 (1) + AM251 (1) | 7 | 10.0 ± 1.8 | 5.2 ± 0.2 | 4.4 ± 0.1 | 63 ± 9 |
URB597 (1) + SR144528 (1) | 6 | 10.9 ± 2.2 | 4.8 ± 0.2 | 4.7 ± 0.1 | 76 ± 10 |
URB597 (1) + capsazepine (1) | 7 | 10.5 ± 1.2 | 4.8 ± 0.1 | 4.5 ± 0.2 | 72 ± 14 |
URB597 (1) + O-1918 (10) | 7 | 10.3 ± 1.5 | 4.4 ± 0.1† | – | 38 ± 3† |
Control (ethanol 0.1 % v/v) | 5 | 7.9 ± 2.0 | 6.0 ± 0.1 | 5.1 ± 0.2 | 97 ± 9 |
Nimesulide (10) | 5 | 7.1 ± 1.0 | 5.2 ± 0.4* | 4.5 ± 0.1* | 75 ± 15 |
Control (1 μM serotonin pre-constricted) | 5 | 8.8 ± 0.5 | 5.3 ± 0.2 | 4.8 ± 0.1 | 85 ± 8 |
Control (60 mM KCl pre-constricted) | 5 | 11.4 ± 2.5 | – | – | 25 ± 12°°° |
Data are expressed as the mean ± SEM of n independent experiments
Some experiments were performed in endothelium-denuded rings (–endothelium). If not stated otherwise, micromolar concentrations of chemicals are provided in brackets
l -NAME N G-nitro-l-arginine methyl ester
*P < 0.05; **P < 0.01; ***P < 0.001, compared with the respective control group; † P < 0.05, compared with URB597 alone; °°° P < 0.001, compared with the control obtained in the presence of U-46619
aRelaxant effect at the highest anandamide concentration (100 μM)